Disitamab vedotin (anti-HER2) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC-HPLC), Lot by Lot
AB183317-100ΜG / 100ΜG
CAS:2136633-23-1
Disitamab vedotin (anti-HER2) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC-HPLC), Lot by Lot
AB183317-10MG / 10MG
CAS:2136633-23-1
Disitamab vedotin (anti-HER2) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC-HPLC), Lot by Lot
AB183317-1MG / 1MG
CAS:2136633-23-1
Disitamab vedotin (anti-HER2) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC-HPLC), Lot by Lot
AB183317-5MG / 5MG
CAS:2136633-23-1
Iladatuzumab vedotin (anti-CD79b) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183320-100ΜG / 100ΜG
CAS:1906205-77-3
Iladatuzumab vedotin (anti-CD79b) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183320-10MG / 10MG
CAS:1906205-77-3
Iladatuzumab vedotin (anti-CD79b) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183320-1MG / 1MG
CAS:1906205-77-3
Iladatuzumab vedotin (anti-CD79b) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183320-5MG / 5MG
CAS:1906205-77-3
Ozuriftamab vedotin (anti-ROR2) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183322-100ΜG / 100ΜG
CAS:2460400-11-5
Ozuriftamab vedotin (anti-ROR2) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183322-10MG / 10MG
CAS:2460400-11-5
Ozuriftamab vedotin (anti-ROR2) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183322-1MG / 1MG
CAS:2460400-11-5
Ozuriftamab vedotin (anti-ROR2) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183322-5MG / 5MG
CAS:2460400-11-5
Pinatuzumab vedotin (anti-CD22) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183323-100ΜG / 100ΜG
CAS:1313706-14-7
Pinatuzumab vedotin (anti-CD22) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183323-10MG / 10MG
CAS:1313706-14-7
Pinatuzumab vedotin (anti-CD22) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183323-1MG / 1MG
CAS:1313706-14-7
Pinatuzumab vedotin (anti-CD22) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183323-5MG / 5MG
CAS:1313706-14-7
Sofituzumab vedotin (anti-MUC16) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183328-100ΜG / 100ΜG
CAS:1418200-58-4
Sofituzumab vedotin (anti-MUC16) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183328-10MG / 10MG
CAS:1418200-58-4
Sofituzumab vedotin (anti-MUC16) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183328-1MG / 1MG
CAS:1418200-58-4
Sofituzumab vedotin (anti-MUC16) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183328-5MG / 5MG
CAS:1418200-58-4
Ladiratuzumab vedotin (anti-SLC39A6) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183329-100ΜG / 100ΜG
CAS:1629760-29-7
Ladiratuzumab vedotin (anti-SLC39A6) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183329-10MG / 10MG
CAS:1629760-29-7
Ladiratuzumab vedotin (anti-SLC39A6) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183329-1MG / 1MG
CAS:1629760-29-7
Ladiratuzumab vedotin (anti-SLC39A6) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183329-5MG / 5MG
CAS:1629760-29-7
Enapotamab vedotin (anti-Axl) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183333-100ΜG / 100ΜG
CAS:1912424-97-5
Enapotamab vedotin (anti-Axl) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183333-10MG / 10MG
CAS:1912424-97-5
Enapotamab vedotin (anti-Axl) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183333-1MG / 1MG
CAS:1912424-97-5
Enapotamab vedotin (anti-Axl) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183333-5MG / 5MG
CAS:1912424-97-5
Telisotuzumab vedotin (anti-c-Met) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183336-100ΜG / 100ΜG
CAS:1714088-51-3
Telisotuzumab vedotin (anti-c-Met) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183336-10MG / 10MG
CAS:1714088-51-3
Telisotuzumab vedotin (anti-c-Met) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183336-1MG / 1MG
CAS:1714088-51-3
Telisotuzumab vedotin (anti-c-Met) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183336-5MG / 5MG
CAS:1714088-51-3
Vorsetuzumab mafodotin (anti-CD70) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183339-100ΜG / 100ΜG
CAS:1165741-01-4
Vorsetuzumab mafodotin (anti-CD70) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183339-10MG / 10MG
CAS:1165741-01-4
Vorsetuzumab mafodotin (anti-CD70) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183339-1MG / 1MG
CAS:1165741-01-4
Vorsetuzumab mafodotin (anti-CD70) ExactAb™, 重組, 已驗證, 無疊氮鈉, 低內毒素, 無載體, ≥90%(SDS-PAGE&SEC), Lot by Lot
AB183339-5MG / 5MG
CAS:1165741-01-4
Atinumab (anti-NOGO) ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
AB183417-100ΜG / 100ΜG
CAS:1226761-65-4
Atinumab (anti-NOGO) ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
AB183417-10MG / 10MG
CAS:1226761-65-4